Results 151 to 160 of about 898,102 (296)

A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics

open access: yesAndrology, EarlyView.
ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis   +3 more
wiley   +1 more source

Mogamulizumab efficacy on the skin compartment of cutaneous T‐cell lymphomas based on longitudinal analysis

open access: yesBritish Journal of Haematology, EarlyView.
Summary Cutaneous T‐cell lymphoma is staged by the degree of skin, lymph node, viscera and blood involvement. Skin response is a determinant of treatment decisions. Mogamulizumab, an anti‐CC chemokine receptor 4 antibody, is approved for mycosis fungoides and Sézary syndrome after ≥1 systemic therapy.
Nobuaki Nakano   +3 more
wiley   +1 more source

Molecular basis for depsipeptide HDAC inhibitor combinatorial biosynthesis. [PDF]

open access: yesNat Commun
Passmore M   +8 more
europepmc   +1 more source

Olfactory proteomics reveals the capacity of the HDAC1 inhibitor pyroxamide to halt the α‐synuclein preformed fibrils‐induced damage in nasal epithelial, microglial and dopaminergic neuronal cell lines

open access: yesBrain Pathology, EarlyView.
Omics‐driven drug repositioning reveals pyroxamide as a neuroprotective HDAC1 inhibitor in Parkinson's disease models. Abstract Parkinson's disease (PD) is the second most common neurodegenerative disorder mainly characterized by the degeneration of dopaminergic neurons originating in the substantia nigra (SN) pars compacta and projecting to other ...
Paz Cartas‐Cejudo   +7 more
wiley   +1 more source

Hydroxamic Acids as HDAC Inhibitor Drug Leads for Malaria. [PDF]

open access: yesMed Res Rev
Dawood WA   +7 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye   +5 more
wiley   +1 more source

Peripheral targets for neuropathic pain

open access: yesBritish Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour   +3 more
wiley   +1 more source

Methyl 4‐O‐Demethylbarbatate Destabilises HIF‐1α and Enhances Temozolomide Sensitivity in Glioma Cells

open access: yesCell Proliferation, EarlyView.
The lichen‐derived metabolite methyl 4‐O‐demethylbarbatate (Me‐4‐O‐DBA) suppresses glioma stemness, motility, and metabolic plasticity through inhibition of HIF‐1α signaling and synergistically enhances temozolomide activity, highlighting a potential strategy to target stemness‐driven therapeutic resistance in glioma.
Rui Zhou   +8 more
wiley   +1 more source

Lactate and Lactylation: What We Know and What We Expect in Tumour Progression

open access: yesCell Proliferation, EarlyView.
Lactate and lactylation in cancer cells have been shown to accelerate tumour development in various ways, including stemness generation, metabolic dysregulation, cell death, chemotherapy resistance, and cell cycle disorder. In addition, lactate and lactylation promote angiogenesis and create an immunosuppressive microenvironment, which promotes tumour ...
Qi Zhang, Zhenzhen Han, Youjia Duan
wiley   +1 more source

Synergistic effects of HDAC inhibitor tucidinostat and ENT inhibitor dipyridamole in T-cell malignancies. [PDF]

open access: yesSci Rep
Li J   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy